Covalent design

Version Compatibility

Reference examples tested with: RDKit 2024.09+, OpenEye / AutoDock Vina 1.2+ (for covalent extensions), GOLD (commercial), DOCKovalent (web service), HCovDock 1.0+.

Before using code patterns, verify installed versions match. If versions differ:

• Python: pip show rdkit then help(rdkit.Chem) to check signatures
• CLI: check version output of each docking tool

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.

Covalent Inhibitor Design

Design molecules that form covalent bonds with target protein residues. The "covalent revolution" (Lonsdale & Ward 2018) made TCIs (Targeted Covalent Inhibitors) clinically validated: KRAS G12C inhibitors (sotorasib, adagrasib), BTK inhibitors (ibrutinib), and EGFR inhibitors (osimertinib) are recent successes. Postdoc-grade covalent design requires balancing intrinsic reactivity (must form bond) vs selectivity (only the intended residue), reversibility (irreversible vs reversible covalent), and drug-likeness (warheads can hurt PK).

For warhead substructure filtering (in non-covalent contexts), see chemoinformatics/substructure-search. For non-covalent docking, see chemoinformatics/virtual-screening. For pose validation, see chemoinformatics/pose-validation.

Reactive Residue Taxonomy

Residue	% of covalent drugs	Reactivity	Notes
Cysteine	~98%	High (nucleophile thiol)	Most accessible; preferred
Lysine	~1%	Moderate (amine)	Less reactive; selective for sulfonyl fluoride
Serine	<1%	Low (alcohol, requires activation)	β-lactam, boronate
Threonine	very rare	Low	Boronate, aldehyde
Tyrosine	very rare	Moderate (phenol)	Sulfonyl fluoride, fluorosulfate
Aspartate/Glutamate	very rare	Low (carboxylate)	Aldehyde Schiff base

Cysteine is the dominant target because:

• Soft nucleophile (matches soft electrophiles)
• Low background reactivity (rare in proteins, ~1.7%)
• Distinguishable from common nucleophiles (GSH, off-target Cys)

Warhead Chemistry

Warhead	SMARTS pattern	Reactivity	Reversibility	Cys-selective
Acrylamide	C(=O)C=C	Moderate (Michael acceptor)	Irreversible	Yes
Chloroacetamide	C(=O)CCl	High (SN2)	Irreversible	Yes
α-haloketone	[CX3](=O)C[F,Cl,Br]	Very high	Irreversible	Yes (but reactive)
Vinyl sulfone	S(=O)(=O)C=C	Moderate (Michael)	Irreversible	Yes
Sulfonyl fluoride	S(=O)(=O)F	Moderate	Irreversible	Lys/Tyr/Ser
Fluorosulfate (SuFEx)	OS(=O)(=O)F	Moderate	Irreversible	Tyr/Lys
Aldehyde	C(=O)[H]	Variable	Reversible (covalent equilibrium)	Cys/Lys/Ser
Boronate (B-OH or B(OH)2)	B(O)O	Moderate	Reversible	Ser/Thr
Nitrile	C#N	Low	Reversible (Cys-S adduct)	Cys
Epoxide	C1OC1	High	Irreversible	Cys/Lys/Asp
α,β-unsaturated ketone	[CX3](=O)C=C	Moderate (Michael)	Irreversible	Cys
Isothiocyanate	N=C=S	High	Irreversible	Cys/Lys
Maleimide	C(=O)N(C(=O))C=C	Very high	Irreversible	Cys
Cysteine-selective heterocycle	various	Moderate	Variable	Yes (designed)

Practical hierarchy: Acrylamide is the modern default for cysteine-selective TCIs (KRAS G12C, EGFR, BTK). Chloroacetamide is more reactive (faster) but less selective.

Decision Tree by Scenario

Goal	Warhead choice	Reactivity tier
Cysteine TCI, drug candidate	Acrylamide	Moderate (~kinact/Ki ~10^3-10^5 M^-1 s^-1)
Cysteine probe (chemical biology)	Chloroacetamide	High (kinact/Ki ~10^4-10^6 M^-1 s^-1)
Lysine TCI (uncommon)	Sulfonyl fluoride	Moderate
Tyrosine TCI	Fluorosulfate (SuFEx)	Moderate
Reversible covalent (KRAS G12C-like)	Acrylamide with α-substitution	Moderate reversibility
Activity-based protein profiling (ABPP)	Iodoacetamide / chloroacetamide	Very high
Boronic acid inhibitor (proteasome)	Boronate	Reversible
Aldehyde inhibitor (calpain)	Aldehyde	Reversible covalent

Kinetics: kinact / Ki

Covalent inhibition kinetics:

• Ki: reversible binding affinity (initial, like non-covalent IC50)
• kinact: rate of covalent bond formation (sec^-1)
• kinact/Ki: second-order rate constant, "covalent efficiency" (M^-1 s^-1)

Modern best practice: report kinact/Ki, not just IC50. Two compounds with same IC50 can have very different kinact/Ki:

• Low Ki, low kinact: tight binding, slow covalent bond
• High Ki, high kinact: loose binding, fast covalent bond

kinact/Ki range (M^-1 s^-1)	Interpretation	Reference
> 10^5	Highly efficient covalent inhibitor	Chloroacetamide probes, fragment-warhead TCIs
10^3 - 10^5	Standard for TCI; clinical candidate	Sotorasib (AMG510) KRAS G12C ~2x10^4 (Hallin 2020); adagrasib ~5x10^3
10^2 - 10^3	Moderate; clinical possible with high target dwell time	Ibrutinib BTK ~5x10^3 (Pan 2007)
< 10^2	Weak; needs warhead optimization	Reversibility likely dominates
<= 10	Probably not covalent (or wrong residue)	Background rate vs GSH

Intrinsic Reactivity Assays

Before committing to a warhead, measure intrinsic reactivity (off-target risk):

# Generic GSH stability assay readout - measure half-life of warhead with 10 mM GSH
# kinact_GSH from time-course of warhead disappearance

Warhead	GSH t1/2 at 10 mM	Risk
Chloroacetamide	minutes	High (reacts with off-target Cys)
Acrylamide	hours	Moderate
Substituted acrylamide (alpha-Me)	days	Low (drug-like)
Nitrile	days	Low
Sulfonyl fluoride	hours-days	Variable

The "GSH-stable" warhead (t1/2 > 4 hours) is the modern target for druglike TCIs.

Covalent Docking Tools

Tool	Approach	Strength	Fails when
DOCKovalent (London et al 2014 Nat Chem Biol 10:1066)	Constraint-based DOCK	Free, well-validated	Browser-based; small library
GOLD covalent (CCDC)	GOLD with covalent constraint	Commercial; selectivity	License cost
AutoDock 4 covalent	AD4 with covalent bond	Open source	Slower than Vina
CovDock (Schrödinger)	Glide-based + covalent	Commercial best	License cost
MOE covalent	Triposite Discovery	Commercial	License cost
HCovDock (Wu Q, Huang S-Y 2023 Briefings Bioinform 24:bbac559)	Hierarchical fragment + covalent	Open; supports many residues	Newer, less validated
ICM-Pro covalent	Active site grid + covalent	Commercial; metal centers	License cost

For open-source covalent docking, HCovDock (2023) is the modern alternative; DOCKovalent is the longstanding standard.

Example: KRAS G12C Inhibitor Design Workflow

Goal: Decorate a co-crystal scaffold with a cysteine-targeting warhead and rank candidates by covalent efficiency.

Approach: Load scaffold SMILES, enumerate acrylamide-bearing analogs, filter by reactivity selectivity, dock under covalent constraint, and rank by kinact/Ki surrogates.

from rdkit import Chem

# Step 1: scaffold from co-crystal (4LRW or AMG510)
scaffold_smi = 'c1ccc(C(=O)NC2=Nc3c(...)cnc23)cc1'
scaffold = Chem.MolFromSmiles(scaffold_smi)

# Step 2: enumerate analogs with acrylamide warhead
def add_acrylamide(scaffold, attachment_atom_idx):
    """Append acrylamide (-NC(=O)C=C) at a hydrogen position"""
    warhead = Chem.MolFromSmiles('NC(=O)C=C')
    # ... combine via Chem.RWMol or fragment combination
    pass

# Step 3: filter for reactive group selectivity
# Step 4: dock with DOCKovalent / GOLD covalent / HCovDock
# Step 5: rank by kinact/Ki surrogate (compute reactive Michael acceptor reactivity)

Reactivity Surrogates (computed without experiment)

For ranking warheads without wet-lab data:

Descriptor	Use case
LUMO energy (DFT)	Michael acceptor reactivity (lower LUMO = more reactive)
Electrophile partial charge	SN2 reactivity
RDKit rdMolDescriptors.CalcLabuteASA	Steric accessibility
AlphaFold3 / Boltz-2 binding pose	Geometric fit to reactive Cys

Goal: Approximate Michael-acceptor reactivity from 2D structure without running DFT.

Approach: Parse the SMILES, locate the acrylamide substructure, count alpha-carbon substituents (more substitution lowers LUMO and slows reactivity), and return a negative count as a relative reactivity proxy.

def acceptor_lumo_surrogate(smi):
    # Crude: count alpha-substituents to acrylamide; more substituents = lower reactivity
    mol = Chem.MolFromSmiles(smi)
    if mol is None:
        return None
    acryl_pat = Chem.MolFromSmarts('[CX3](=O)[CX3]=[CX3]')
    matches = mol.GetSubstructMatches(acryl_pat)
    if not matches:
        return None
    # Count substituents on alpha-C
    alpha_c = mol.GetAtomWithIdx(matches[0][1])
    n_subs = len([n for n in alpha_c.GetNeighbors() if n.GetIdx() not in matches[0]])
    return -n_subs  # crude proxy (lower = more reactive)

For real reactivity prediction, DFT calculations (LUMO energy, HOMO-LUMO gap) are needed.

Per-Tool Failure Modes

Wrong warhead for residue

Trigger: Acrylamide warhead targeted at Tyr.

Mechanism: Acrylamides are Cys-selective; do not form bonds with Tyr at physiological pH.

Symptom: No covalent adduct observed despite docking pose.

Fix: Match warhead to residue: acrylamide/chloroacetamide for Cys; sulfonyl fluoride for Lys/Tyr/Ser.

Excessive reactivity (off-target)

Trigger: Chloroacetamide in drug-candidate context.

Mechanism: Too reactive; forms adducts with off-target Cys (e.g., GSH t1/2 < 30 min).

Symptom: Toxicity in cell-based assays; non-specific binding signal.

Fix: Replace with acrylamide (more selective); add alpha-substitution to acrylamide for tunable reactivity.

Geometric mismatch

Trigger: Warhead positioned but Cys-Cβ distance > 6 Å.

Mechanism: Even with reactive warhead, geometric reach matters; Cys side chain has limited reach.

Symptom: No covalent labeling in mass spec despite predicted docking.

Fix: Validate by measuring distance from warhead to Cys-Cβ; redock with constrained covalent bond.

Reversibility unintended

Trigger: Designed irreversible TCI but warhead is reversible.

Mechanism: Nitrile, aldehyde, boronate are reversible; equilibrium with non-covalent.

Symptom: Activity wanes after substrate washout in cellular assays.

Fix: Use truly irreversible warhead (acrylamide, chloroacetamide); or design for reversible covalent intentionally.

kinact/Ki conflation

Trigger: Optimizing for IC50 instead of kinact/Ki.

Mechanism: Compounds with same IC50 differ in covalent efficiency.

Symptom: Apparently identical compounds have different in vivo PK.

Fix: Always measure kinact/Ki (kinetic assay); rank by covalent efficiency.

DOCKovalent over-prediction

Trigger: Default DOCKovalent run.

Mechanism: Covalent constraint forces docking; many ligands "succeed" but are unrealistic.

Symptom: Many compounds pass docking; few label in vitro.

Fix: Post-filter by reactivity (chemoinformatics), geometric fit (Cys-Cβ distance), and PoseBusters.

Reconciliation: Irreversible vs Reversible Covalent

Aspect	Irreversible	Reversible covalent
Examples	KRAS G12C (acrylamide), BTK (ibrutinib)	Boronate (bortezomib), aldehyde (calpain inhibitors)
Toxicity profile	Off-target Cys labeling potential	Off-target equilibrium
Resistance mechanism	Mutation of reactive Cys	Mutation reduces affinity
Patent / IP	Stronger (specific bond)	Standard
When to choose	If Cys is hot-spot, conserved, druggable	If reversibility critical (e.g., proteasome)

Common Errors

Symptom	Cause	Fix
Warhead not matching SMARTS	Different stereochemistry or charged	Use canonicalized + neutral SMARTS
DOCKovalent rejects ligand	No suitable Cys in pocket	Re-check residue accessibility
GSH adduct dominates	Warhead too reactive	Use less reactive warhead; or alpha-substitute
Off-target labeling in cells	Promiscuous warhead	Iterate warhead reactivity vs selectivity
Docking pose but no labeling	Geometric mismatch	Distance check; rotamer search
Reversible inhibitor not acting irreversibly	Wrong warhead class	Re-check reaction mechanism
HCovDock fails on PROTAC	Tool optimized for monomer covalent	Use specialized tools for bivalent

References

• Lonsdale & Ward, Chem. Soc. Rev. 47:3816 (2018) -- covalent revolution review.
• Singh et al., Nat. Rev. Drug Discov. 10:307 (2011) -- TCI design principles.
• London et al., Nat Chem Biol 10:1066-1072 (2014) -- DOCKovalent.
• Wu Q, Huang S-Y et al., Briefings Bioinform. 24:bbac559 (2023) -- HCovDock.
• Cai et al., J. Cheminformatics 14:39 (2022) -- GOLD covalent toolkit.
• Backus et al., Nat. Chem. 8:530 (2016) -- proteome-wide covalent ABPP.
• Pettinger et al., Angew. Chem. Int. Ed. 56:15200 (2017) -- reactive warhead reactivity quantification.
• Schwartz et al., Nat. Chem. Biol. 10:1006 (2014) -- KRAS G12C disulfide-tethered fragments.

Related Skills

• chemoinformatics/molecular-io - Parse warhead SMILES
• chemoinformatics/substructure-search - Warhead SMARTS detection
• chemoinformatics/virtual-screening - Pre-dock candidate non-covalent fit
• chemoinformatics/pose-validation - Validate covalent docking
• chemoinformatics/conformer-generation - Warhead conformer ensembles
• chemoinformatics/admet-prediction - ADMET of covalent leads
• chemoinformatics/molecular-descriptors - Reactivity surrogate descriptors